Intuitive Announces First Quarter Earnings
Intuitive (Nasdaq: ISRG) reported Q1 2022 results, revealing revenue of $1.49 billion, up 15% from $1.29 billion in Q1 2021. The increase was driven by a 19% rise in da Vinci procedures. The company placed 311 da Vinci Surgical Systems, marking a 4% increase. However, GAAP net income fell to $366 million ($1.00 per share), down from $426 million ($1.17 per share) in the prior year. COVID-19 continued to impact procedure volumes, but customer demand remained strong. The company ended the quarter with $8.40 billion in cash and investments.
- Q1 2022 revenue increased by 15% to $1.49 billion.
- da Vinci procedures rose approximately 19% compared to Q1 2021.
- Placed 311 da Vinci Surgical Systems, up 4% year-over-year.
- Instruments and accessories revenue increased by 15% to $810 million.
- GAAP net income decreased to $366 million from $426 million year-over-year.
- GAAP income from operations fell to $408 million from $417 million in the previous year.
SUNNYVALE, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2022. All prior year per-share information has been retroactively adjusted to reflect a three-for-one stock split.
Q1 Highlights
- Worldwide da Vinci procedures grew approximately
19% compared with the first quarter of 2021. The first quarter of 2021 reflected disruption caused by the COVID-19 pandemic, and the first quarter of 2022 reflected another COVID-19 resurgence, which also impacted our procedures. The compound annual growth rate between the first quarter of 2019 and the first quarter of 2022 was approximately15% . - The Company placed 311 da Vinci Surgical Systems, an increase of
4% compared with 298 in the first quarter of 2021. - The Company grew its da Vinci Surgical System installed base to 6,920 systems as of March 31, 2022, an increase of
13% compared with 6,142 as of the end of the first quarter of 2021. - First quarter 2022 revenue of
$1.49 billion increased15% compared with$1.29 billion in the first quarter of 2021. The compound annual growth rate between the first quarter of 2019 and the first quarter of 2022 was15% . - First quarter 2022 GAAP net income attributable to Intuitive was
$366 million , or$1.00 per diluted share, compared with$426 million , or$1.17 per diluted share, in the first quarter of 2021. - First quarter 2022 non-GAAP* net income attributable to Intuitive was
$413 million , or$1.13 per diluted share, compared with$427 million , or$1.17 per diluted share, in the first quarter of 2021.
Q1 Financial Summary
Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., net income per diluted share attributable to Intuitive Surgical, Inc., and diluted shares are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.
First quarter 2022 revenue was
First quarter 2022 instruments and accessories revenue increased by
First quarter 2022 systems revenue increased by
First quarter 2022 GAAP income from operations decreased to
First quarter 2022 GAAP net income attributable to Intuitive Surgical, Inc. was
First quarter 2022 non-GAAP* net income attributable to Intuitive Surgical, Inc. was
The Company ended the first quarter of 2022 with
Impact of COVID-19 Pandemic
During 2021 and 2022, COVID-19 resurgences continued to impact da Vinci procedure volumes. The impact of the COVID-19 pandemic on the Company’s business has, and continues to, differ by geography and region. COVID-19 has had, and will likely continue to have, an adverse impact on the Company’s procedure volumes.
Commenting on the announcement, Intuitive CEO Gary Guthart said, “Customer demand for our products was healthy in the first quarter despite a challenging global environment. We remain focused on meeting that demand with high quality products and services while advancing our innovation programs.”
Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at https://isrg.gcs-web.com/.
Webcast and Conference Call Information
Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the first quarter 2022 financial results. The call will be webcast by Nasdaq OMX and can be accessed on Intuitive’s website at www.intuitive.com or by dialing (877) 692-8955 using the access code 5830756. The webcast replay of the call will be made available on our website at www.intuitive.com within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.
About Intuitive
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. As part of our mission, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.
Intuitive brings nearly three decades of leadership in robotic-assisted surgical technology and solutions to its offerings and develops, manufactures, and markets the da Vinci Surgical System and the Ion endoluminal system.
Product and brand names/logos are trademarks or registered trademarks of Intuitive Surgical or their respective owner. See www.intuitive.com/trademarks.
For more information, please visit the Company’s website at www.intuitive.com.
Forward-Looking Statements
This press release contains forward-looking statements. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to the expected impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, future results of operations, future financial position, our financing plans and future capital requirements, our potential tax assets or liabilities, and statements based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and our beliefs and assumptions regarding these economies and markets. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: disruption to our supply chain, including increased difficulties in obtaining a sufficient supply of materials in the semiconductor and other markets, the risk that the COVID-19 pandemic could lead to material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by hospitals; closures of our facilities; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals, clearances, or certifications from the U.S. Food and Drug Administration (“FDA”); the evaluation of the risks of robotic-assisted surgery in the presence of infectious diseases; diversion of resources to respond to COVID-19 outbreaks; the risk that the COVID-19 virus causes economies in our key markets to enter prolonged recessions; the impact of global and regional economic and credit market conditions on healthcare spending; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; risks associated with our operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party, including but not limited to product liability claims; adverse publicity regarding us and the safety of our products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as updated by the Company’s other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
*About Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., non-GAAP net income per diluted share attributable to Intuitive Surgical, Inc. (“EPS”), and non-GAAP diluted shares outstanding. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (“SBC”) and long-term incentive plan expenses, and other special items. Long-term incentive plan expense relates to phantom share awards granted in China by the Company’s joint venture, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to its employees that vest over four years and can remain outstanding for seven to ten years. These awards are valued based on certain key performance metrics. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Company’s business within the period. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.
Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit, excluding amortization of intangible assets and SBC and long-term incentive plan expenses.
Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations, excluding amortization of intangible assets, SBC and long-term incentive plan expenses, and a gain on the sale of a business.
Non-GAAP net income attributable to Intuitive Surgical, Inc. and EPS. The Company defines non-GAAP net income as net income attributable to Intuitive Surgical, Inc., excluding amortization of intangible assets, SBC and long-term incentive plan expenses, a gain on the sale of a business, gains (losses) on strategic investments, adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects, and tax adjustments, including the excess tax benefits or deficiencies associated with SBC arrangements and the net tax effects related to intra-entity transfers of non-inventory assets. The Company excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the on-going results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income attributable to Intuitive Surgical, Inc. divided by non-GAAP diluted shares, which are calculated as GAAP weighted-average outstanding shares plus dilutive potential shares outstanding during the period.
There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP EPS exclude items such as amortization of intangible assets, re-measurement of contingent consideration, SBC and long-term incentive plan expenses, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS together with net income attributable to Intuitive Surgical, Inc. and net income per share attributable to Intuitive Surgical, Inc. calculated in accordance with GAAP.
| INTUITIVE SURGICAL, INC. UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA)* | |||||||||||
| Three Months Ended | |||||||||||
| March 31, 2022 | December 31, 2021 | March 31, 2021 | |||||||||
| Revenue: | |||||||||||
| Instruments and accessories | $ | 810.3 | $ | 842.8 | $ | 705.9 | |||||
| Systems | 428.1 | 469.9 | 368.7 | ||||||||
| Services | 249.3 | 238.0 | 217.5 | ||||||||
| Total revenue | 1,487.7 | 1,550.7 | 1,292.1 | ||||||||
| Cost of revenue: | |||||||||||
| Product | 397.3 | 414.9 | 319.3 | ||||||||
| Service | 80.7 | 75.0 | 70.2 | ||||||||
| Total cost of revenue | 478.0 | 489.9 | 389.5 | ||||||||
| Gross profit | 1,009.7 | 1,060.8 | 902.6 | ||||||||
| Operating expenses: | |||||||||||
| Selling, general and administrative (1) | 391.1 | 427.0 | 326.0 | ||||||||
| Research and development | 210.5 | 183.4 | 159.8 | ||||||||
| Total operating expenses | 601.6 | 610.4 | 485.8 | ||||||||
| Income from operations (2) | 408.1 | 450.4 | 416.8 | ||||||||
| Interest and other income (expense), net (3) | (5.7 | ) | 3.8 | 32.0 | |||||||
| Income before taxes | 402.4 | 454.2 | 448.8 | ||||||||
| Income tax expense (4) | 33.0 | 71.5 | 13.6 | ||||||||
| Net income | 369.4 | 382.7 | 435.2 | ||||||||
| Less: net income attributable to noncontrolling interest in joint venture | 3.8 | 2.1 | 8.9 | ||||||||
| Net income attributable to Intuitive Surgical, Inc. | $ | 365.6 | $ | 380.6 | $ | 426.3 | |||||
| Net income per share attributable to Intuitive Surgical, Inc.: | |||||||||||
| Basic | $ | 1.02 | $ | 1.06 | $ | 1.20 | |||||
| Diluted (5) | $ | 1.00 | $ | 1.04 | $ | 1.17 | |||||
| Weighted average shares outstanding: | |||||||||||
| Basic | 358.4 | 357.5 | 354.2 | ||||||||
| Diluted | 366.7 | 367.4 | 364.0 | ||||||||
| (1) Selling, general and administrative includes the effect of the following item: | |||||||||||
| Contributions to the Intuitive Foundation | $ | — | $ | (30.0 | ) | $ | — | ||||
| (2) Income from operations includes the effect of the following item: | |||||||||||
| Amortization of intangible assets | $ | (6.1 | ) | $ | (6.6 | ) | $ | (6.9 | ) | ||
| Expensed IP charged to R&D | $ | (7.8 | ) | $ | (5.0 | ) | $ | (1.2 | ) | ||
| (3) Interest and other income (expense), net includes the effect of the following item: | |||||||||||
| Gains (losses) on strategic investments | $ | (17.3 | ) | $ | (7.5 | ) | $ | 14.3 | |||
| (4) Income tax expense (benefit) includes the effect of the following items: | |||||||||||
| Excess tax benefits related to share-based compensation arrangements | $ | (53.0 | ) | $ | (26.9 | ) | $ | (73.4 | ) | ||
| (5) Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items: | |||||||||||
| Contributions to the Intuitive Foundation, net of tax | $ | — | $ | (0.06 | ) | $ | — | ||||
| Amortization of intangible assets, net of tax | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.02 | ) | ||
| Expensed IP charged to R&D, net of tax | $ | (0.02 | ) | $ | (0.01 | ) | $ | — | |||
| Gains (losses) on strategic investments, net of tax | $ | (0.04 | ) | $ | (0.02 | ) | $ | 0.03 | |||
| Excess tax benefits related to share-based compensation arrangements | $ | 0.14 | $ | 0.07 | $ | 0.20 | |||||
| (*) Shares issued pursuant to the three-for-one stock split of the Company’s issued and outstanding common stock, par value | |||||||||||
| INTUITIVE SURGICAL, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (IN MILLIONS) | |||||
| March 31, 2022 | December 31, 2021 | ||||
| Cash, cash equivalents, and investments | $ | 8,401.8 | $ | 8,619.5 | |
| Accounts receivable, net | 906.1 | 782.7 | |||
| Inventory | 653.0 | 587.1 | |||
| Property, plant, and equipment, net | 1,968.2 | 1,876.4 | |||
| Goodwill | 343.2 | 343.6 | |||
| Deferred tax assets | 485.4 | 441.4 | |||
| Other assets | 920.7 | 904.3 | |||
| Total assets | $ | 13,678.4 | $ | 13,555.0 | |
| Accounts payable and other accrued liabilities | $ | 1,097.1 | $ | 1,189.5 | |
| Deferred revenue | 424.4 | 414.0 | |||
| Total liabilities | 1,521.5 | 1,603.5 | |||
| Stockholders’ equity | 12,156.9 | 11,951.5 | |||
| Total liabilities and stockholders’ equity | $ | 13,678.4 | $ | 13,555.0 | |
| INTUITIVE SURGICAL, INC. UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (IN MILLIONS, EXCEPT PER SHARE DATA)* | ||||||||||||
| Three Months Ended | ||||||||||||
| March 31, 2022 | December 31, 2021 | March 31, 2021 | ||||||||||
| GAAP gross profit | $ | 1,009.7 | $ | 1,060.8 | $ | 902.6 | ||||||
| Share-based compensation expense | 24.0 | 22.4 | 20.7 | |||||||||
| Long-term incentive plan expense | 0.3 | 0.7 | — | |||||||||
| Amortization of intangible assets | 3.8 | 3.9 | 4.5 | |||||||||
| Non-GAAP gross profit | $ | 1,037.8 | $ | 1,087.8 | $ | 927.8 | ||||||
| GAAP income from operations | $ | 408.1 | $ | 450.4 | $ | 416.8 | ||||||
| Share-based compensation expense | 120.8 | 117.8 | 103.6 | |||||||||
| Long-term incentive plan expense | 2.0 | 8.1 | — | |||||||||
| Amortization of intangible assets (1) | 6.1 | 6.6 | 6.9 | |||||||||
| Gain on sale of business | (3.8 | ) | — | — | ||||||||
| Non-GAAP income from operations | $ | 533.2 | $ | 582.9 | $ | 527.3 | ||||||
| GAAP net income attributable to Intuitive Surgical, Inc. | $ | 365.6 | $ | 380.6 | $ | 426.3 | ||||||
| Share-based compensation expense | 120.8 | 117.8 | 103.6 | |||||||||
| Long-term incentive plan expense | 2.0 | 8.1 | — | |||||||||
| Amortization of intangible assets (1) | 6.1 | 6.6 | 6.9 | |||||||||
| Gain on sale of business | (3.8 | ) | — | — | ||||||||
| (Gains) losses on strategic investments | 17.2 | 7.3 | (14.3 | ) | ||||||||
| Tax adjustments (2) | (93.9 | ) | (44.4 | ) | (94.9 | ) | ||||||
| Adjustments attributable to noncontrolling interest in joint venture | (0.9 | ) | (3.4 | ) | (0.4 | ) | ||||||
| Non-GAAP net income attributable to Intuitive Surgical, Inc. | $ | 413.1 | $ | 472.6 | $ | 427.2 | ||||||
| GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted | $ | 1.00 | $ | 1.04 | $ | 1.17 | ||||||
| Share-based compensation expense | 0.33 | 0.32 | 0.28 | |||||||||
| Long-term incentive plan expense | — | 0.02 | — | |||||||||
| Amortization of intangible assets (1) | 0.02 | 0.02 | 0.02 | |||||||||
| Gain on sale of business | (0.01 | ) | — | — | ||||||||
| (Gains) losses on strategic investments | 0.05 | 0.02 | (0.04 | ) | ||||||||
| Tax adjustments (2) | (0.26 | ) | (0.12 | ) | (0.26 | ) | ||||||
| Adjustments attributable to noncontrolling interest in joint venture | — | (0.01 | ) | — | ||||||||
| Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted | $ | 1.13 | $ | 1.29 | $ | 1.17 | ||||||
| (1) Beginning with the quarter ended March 31, 2022, the Company will no longer adjust non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., or non-GAAP net income per share attributable to Intuitive Surgical, Inc. for charges relating to intellectual property and license arrangements expensed to R&D. The Company is making these changes to its presentation of non-GAAP financial measures based on its understanding of the U.S. Securities and Exchange Commission’s (the “SEC”) current views on this practice from knowledge of recent communications between the SEC and a number of pharmaceutical and life sciences companies and independent registered public accounting firms. Historical non-GAAP measures presented in our earnings release have been adjusted for comparability. The impact of this adjustment is an increase to non-GAAP R&D expenses and a decrease of non-GAAP income from operations of | ||||||||||||
| (2) For the three months ended March 31, 2022, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of | ||||||||||||
| (*) Shares issued pursuant to the three-for-one stock split of the Company’s issued and outstanding common stock, par value | ||||||||||||
Contact: Investor Relations
(408) 523-2161
FAQ
What were Intuitive's Q1 2022 earnings results for ISRG?
How did the COVID-19 pandemic impact ISRG's operations in Q1 2022?
What is the outlook for Intuitive following the Q1 2022 report?
How many da Vinci Surgical Systems were placed in Q1 2022?
What was the cash position of Intuitive as of Q1 2022?
